

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 3 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

Amendments to the Claims:

This listing of the claims below will replace all prior versions and listing of claims in this application.

Listing of Claims:

CLAIMS 1-282. (CANCELLED)

CLAIM 283. (PREVIOUSLY PRESENTED) A composition of matter comprising:

a first part which comprises a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

a second part which comprises one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal.

CLAIM 284. (PREVIOUSLY PRESENTED) A composition of matter comprising:

a first part which comprises an analyte having one or more molecularly recognizable portions thereon;

a second part which comprises a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable analyte portion, and a second portion comprising one or more nucleic acid sequences or segments; and

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 4 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

a third part which comprises one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion or portions on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal.

CLAIM 285. (PREVIOUSLY PRESENTED) A composition of matter comprising:
a complex which comprises:

a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal.

CLAIM 286. (PREVIOUSLY PRESENTED) A composition of matter comprising:
a complex which comprises:

an analyte having one or more molecularly recognizable portions thereon;

a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable analyte portion and a second portion comprising one or more nucleic acid sequences or segments; and

one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte,

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serlal No.: 08/479,995 (Filed June 7, 1995)

Page 5 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal.

CLAIM 287. (PREVIOUSLY PRESENTED) A composition of matter comprising:

a first part which comprises more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

a second part which comprises one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said more than one bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal.

CLAIM 288. (PREVIOUSLY PRESENTED) A composition of matter comprising:

a first part which comprises an analyte having one or more molecularly recognizable portions thereon;

a second part which comprises more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable analyte portion and a second portion comprising one or more nucleic acid sequences or segments; and

a third part which comprises one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said more than one bridging entity nucleic acid

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 6 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

second portion, and one or more signal generating portions capable of providing a detectable signal.

CLAIM 289. (PREVIOUSLY PRESENTED) A composition of matter comprising a complex which comprises:

more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said more than one bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal.

CLAIM 290. (PREVIOUSLY PRESENTED) A composition of matter comprising a complex which comprises:

an analyte having one or more molecularly recognizable portions thereon;

more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable analyte portion, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said more than one bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 7 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 291. (PREVIOUSLY PRESENTED) A composition of matter comprising:

a first part which comprises a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

a second part which comprises one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more chemically modified or artificially altered polynucleotides capable of providing a detectable signal.

CLAIM 292. (PREVIOUSLY PRESENTED) A composition of matter comprising a complex which comprises:

a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more chemically modified or artificially altered polynucleotides capable of providing a detectable signal.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 8 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 293. (PREVIOUSLY PRESENTED) A composition of matter comprising:

a first part which comprises an analyte having one or more molecularly recognizable portions thereon;

a second part which comprises a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

a third part which comprises one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more chemically modified or artificially altered polynucleotides capable of providing a detectable signal.

CLAIM 294. (PREVIOUSLY PRESENTED) A composition of matter comprising:

a complex which comprises:

an analyte having one or more molecularly recognizable portions thereon;

a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more chemically modified or artificially altered polynucleotides capable of providing a detectable signal.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 9 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 295. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said analyte comprises a biological system.

CLAIM 296. (PREVIOUSLY PRESENTED) The composition according to claim 295, wherein said biological system comprises at least one member selected from the group consisting of a virus or a viral component thereof, and a cell or a cellular component thereof.

CLAIM 297. (PREVIOUSLY PRESENTED) The composition according to claim 296, wherein said cell or component thereof comprises a bacterium or a bacterial component thereof.

CLAIM 298. (PREVIOUSLY PRESENTED) The composition according to claim 295, wherein said biological system comprises a pathogen or a component thereof.

CLAIM 299. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said analyte is selected from the group consisting of a nucleic acid and a protein.

CLAIM 300. (PREVIOUSLY PRESENTED) The composition according to claim 299, wherein said analyte nucleic acid is selected from the group consisting of an oligo- or polyribonucleotide, an oligo- or polydeoxyribonucleotide, a poly-purine, a poly-pyrimidine, and a nucleotide analog-containing nucleic acid polymer, or any combination of the foregoing.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 10 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 301. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said molecular bridging recognizing first portion comprises a low molecular weight organic compound.

CLAIM 302. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said molecular bridging recognizing first portion is selected from the group consisting of an antigen and an antibody.

CLAIM 303. (PREVIOUSLY PRESENTED) The composition according to claim 302, wherein said antibody comprises a polyclonal or a monoclonal antibody.

CLAIM 304. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said molecular bridging recognizing first portion is selected from the group consisting of a saccharide and a lectin.

CLAIM 305. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said molecular bridging recognizing first portion is selected from the group consisting of a hormone and a receptor therefor.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 11 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 306. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said molecular bridging recognizing first portion is selected from the group consisting of an enzyme, an allosteric effector, an enzyme substrate and an enzyme cofactor.

CLAIM 307. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said molecular bridging recognizing first portion is selected from the group consisting of a ligand and a receptor therefor.

CLAIM 308. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said molecular bridging recognizing first portion is selected from the group consisting of a protein and a protein receptor therefor.

CLAIM 309. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said molecular bridging recognizing first portion comprise a nucleic acid.

CLAIM 310. (PREVIOUSLY PRESENTED) The composition according to claim 309, wherein said nucleic acid comprises an oligo- or polynucleotide.

CLAIM 311. (PREVIOUSLY PRESENTED) The composition according to claim 310, wherein said oligo- or polynucleotide comprises a modified oligo- or polynucleotide.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 12 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 312. (PREVIOUSLY PRESENTED) The composition according to claim 310 wherein said oligo- or polynucleotide comprises one or more nucleotides modified on the sugar phosphate, base, or combinations thereof.

CLAIM 313. (PREVIOUSLY PRESENTED) The composition according to claim 310, wherein said oligo- or polynucleotide is single-stranded or partially double-stranded.

CLAIM 314. (PREVIOUSLY PRESENTED) The composition according to claim 310, wherein said oligo- or polynucleotide is circular or linear.

CLAIM 315. (PREVIOUSLY PRESENTED) The composition according to claim 310, wherein said oligo- or polynucleotide is selected from the group consisting of an oligo- or polyribonucleotide, an oligo- or polydeoxyribonucleotide, a poly-purine, a poly-pyrimidine and a nucleotide analog-containing oligo- or polynucleotide, or any combination of the foregoing.

CLAIM 316. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said nucleic acid sequence or segment in the molecular bridging entity second portion comprises an oligo- or polynucleotide.

CLAIM 317. (PREVIOUSLY PRESENTED) The composition according to claim 315, wherein said oligo- or polynucleotide comprises a modified oligo- or polynucleotide.

CLAIM 318. (PREVIOUSLY PRESENTED) The composition according to claim 316, wherein said oligo- or polynucleotide comprises one or more nucleotides modified on the sugar, phosphate, base or combinations thereof.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 13 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 319. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said nucleic acid sequences or segments in the molecular bridging entity second portion is single-stranded or partially double-stranded.

CLAIM 320. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said nucleic acid sequences or segments in the molecular bridging entity second portion is linear or circular.

CLAIM 321. (PREVIOUSLY PRESENTED) The composition according to claim 316, wherein said oligo- or polynucleotide is selected from the group consisting of an oligo- or polyribonucleotide, an oligo- or polydeoxyribonucleotide, a poly-purine, a poly-pyrimidine and a nucleotide analog-containing oligo- or polynucleotide, or any combination of the foregoing.

CLAIM 322. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said nucleic acid sequences or segments in the molecular bridging entity second portion is derived from a phage selected from the group consisting of a T even phage, a filamentous phage, an M13 phage, or, an M13 phage variant.

CLAIM 323. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said molecular bridging entity second portion comprises a nucleic acid sequence or segment of repeating low complexity.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 14 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 324. (PREVIOUSLY PRESENTED) The composition according to claim 323, wherein said nucleic acid sequence or segment of repeating low complexity is selected from the group consisting of a poly G or polydeoxy G, poly GT or polydeoxy GT, poly C or polydeoxy C, poly T or polydeoxy T, poly A or polydeoxy A, poly CA or polydeoxy CA, poly GA or polydeoxy GA, poly GAT or polydeoxy GAT, and poly GTA or polydeoxy GTA.

CLAIM 325. (PREVIOUSLY PRESENTED) The composition according to claim 310, wherein said molecular bridging entity first portion and said molecular bridging entity nucleic acid second portion are incapable of hybridizing to identical oligo- or polynucleotide sequences.

CLAIM 326. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said nucleic acid sequences or segments in the molecular bridging entity second portion are covalently attached to one another.

CLAIM 327. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said signalling entity nucleic acid portion comprises an oligo- or polynucleotide.

CLAIM 328. (PREVIOUSLY PRESENTED) The composition according to claim 327, wherein said signalling entity oligo- or polynucleotide is selected from the group consisting of an oligo- or polyribonucleotide, an oligo- or polydeoxyribonucleotide, a poly-purine, a poly-pyrimidine and a nucleotide analog-containing oligo- or polynucleotide, or any combination of the foregoing.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 15 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 329. (PREVIOUSLY PRESENTED) The composition according to claim 327, wherein said oligo- or polynucleotide comprises a modified oligo- or polynucleotide.

CLAIM 330. (PREVIOUSLY PRESENTED) The composition according to claim 327, wherein said oligo- or polynucleotide comprises one or more nucleotides modified on the sugar, phosphate, base or combinations thereof.

CLAIM 331. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said signalling entity nucleic acid portion is single-stranded or partially double-stranded.

CLAIM 332. (PREVIOUSLY PRESENTED) The composition according to any of the claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said signalling entity nucleic acid portion is linear or circular.

CLAIM 333. (PREVIOUSLY PRESENTED) The composition according to claim 332, wherein said signalling entity nucleic acid portion is a polymer derived from a linear or circular nucleic acid molecule covalently attached to a signal generating portion or a signalling chemical moiety.

CLAIM 334. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said signalling entity nucleic acid portion is derived from a phage selected from the group consisting of a T even phage, a filamentous phage, and an M 13 phage, or an M13 phage variant.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 16 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 335. (PREVIOUSLY PRESENTED) The composition according to claim 329, wherein said signalling entity modified oligo- or polynucleotide comprises a naturally occurring modified oligo- or polynucleotide.

CLAIM 336. (PREVIOUSLY PRESENTED) The composition according to claim 335, wherein said signalling entity modified oligo- or polynucleotide carries a cloned insert.

CLAIM 337. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said signalling entity nucleic acid portion comprises a nucleic acid sequence or segment of repeating low complexity.

CLAIM 338. (PREVIOUSLY PRESENTED) The composition according to claim 337, wherein said nucleic acid sequence or segment of repeating low complexity is selected from the group consisting of a poly G or polydeoxy G, poly GT or polydeoxy GT, poly C or polydeoxy C, poly T or polydeoxy T, poly A or polydeoxy A, poly CA or polydeoxy CA, poly GA or polydeoxy GA, poly GAT or polydeoxy GAT, and poly GTA or polydeoxy GTA.

CLAIM 339. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said signal generating portion or said one or more chemically modified or artificially altered polynucleotides are capable of directly providing a detectable signal.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 17 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 340. (PREVIOUSLY PRESENTED) The composition according to claim 339, wherein said direct signal providing signal generating portion comprises a radioactive compound.

CLAIM 341. (PREVIOUSLY PRESENTED) The composition according to claim 339, wherein said direct signal providing signal generating portion is selected from the group consisting of a fluorogenic compound, a phosphorescent compound, a chromogenic compound, a chemiluminescent compound and an electron dense compound.

CLAIM 342. (PREVIOUSLY PRESENTED) The composition according to claim 339, wherein said direct signal providing signal generating portion comprises an enzyme.

CLAIM 343. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said signal generating portion or said one or more chemically modified or artificially altered polynucleotides are indirectly capable of indirectly providing a detectable signal.

CLAIM 344. (PREVIOUSLY PRESENTED) The composition according to claim 343, wherein said indirect signal providing signal generating portion is selected from the group consisting of an antibody, an antigen, a hapten, a receptor, a ligand and an enzyme.

CLAIM 345. (PREVIOUSLY PRESENTED) The composition according to claim 343, wherein said indirect signal providing signal generating portion comprises a polynucleotide sequence capable of recognizing a signal-containing moiety.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 18 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 346. (PREVIOUSLY PRESENTED) The composition according to claim 343, wherein said indirect signal providing signal generating portion comprises a compound capable of binding to an insoluble phase.

CLAIM 347. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said signal generating portion or said one or more chemically modified or artificially altered polynucleotides are capable of being detected by a member selected from the group consisting of an enzymatic measurement, a fluorescent measurement, a phosphorescent measurement, a chemiluminescent measurement, a colorimetric measurement, a microscopic measurement, an electron density measurement, and a radioactive measurement.

CLAIM 348. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity is greater than 5.

CLAIM 349. (PREVIOUSLY PRESENTED) The composition according to claim 348, wherein the ratio is greater than 10.

CLAIM 350. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein the ratio of the signal generating portions or the one or more chemically modified or artificially altered polynucleotides to the nucleic acid portion in any or all of the signalling entities is greater than 1.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 19 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 351. (PREVIOUSLY PRESENTED) The composition according to claim 350, wherein the ratio is greater than 5.

CLAIM 352. (PREVIOUSLY PRESENTED) The composition according to claim 351, wherein the ratio is greater than 10.

CLAIM 353. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein both the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity is greater than 1, and the ratio of the signal generating portions or the one or more chemically modified or artificially altered polynucleotides to the nucleic acid portion in any or all of the signalling entities are greater than 1.

CLAIM 354. (PREVIOUSLY PRESENTED) The composition according to claim 353, wherein one or both ratios are greater than 5.

CLAIM 355. (PREVIOUSLY PRESENTED) The composition according to claim 354, wherein one or both ratios are greater than 10.

CLAIM 356. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein the ratio of signalling entities to molecular bridging entity is greater than 5.

CLAIM 357. (PREVIOUSLY PRESENTED) The composition according to claim 356, wherein the ratio is greater than 10.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 20 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 358. (PREVIOUSLY PRESENTED) The composition according to any of claims 284, 286, 288, 290, 293 or 294, wherein the analyte is immobilized.

CLAIM 359. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein the molecular bridging entity is immobilized.

CLAIM 360. (PREVIOUSLY PRESENTED) An article of manufacture comprising:
a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and
more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity second portion nucleic acid sequences or segments, and one or more signal generating portions, each capable of providing a detectable signal.

CLAIM 361. (PREVIOUSLY PRESENTED) An article of manufacture comprising:
a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and
more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity second portion nucleic acid sequences or segments, and one or more polynucleotides which have been chemically modified or artificially altered.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 21 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 362. (PREVIOUSLY PRESENTED) The article of manufacture according to claims 360 or 361, further comprising the analyte.

CLAIM 363. (CANCELLED)

CLAIM 364. (PREVIOUSLY PRESENTED) The process according to claims 443, 445 or 447 characterized in that said forming step comprises contacting said analyte with said bridging entity to form a first complex and thereafter contacting the first complex with said signalling entity to form said complex recited in said forming step.

CLAIM 365. (PREVIOUSLY PRESENTED) The process according to claims 443, 445 or 447, characterized in that said forming step comprises contacting said bridging entity with said signalling entity under conditions sufficient to form a first complex and thereafter contacting the first complex with said analyte under conditions sufficient to form said complex recited in said forming step.

366. (CANCELED)

CLAIM 367. (PREVIOUSLY PRESENTED) The process according to claim 366, wherein said detecting step the direct detectable signal provided by said signal generating portion comprises a radioactive compound.

CLAIM 368. (PREVIOUSLY PRESENTED) The process according to claim 366, wherein said detecting step the direct detectable signal is provided by a member selected from the group consisting of a fluorogenic compound, a phosphorescent

Enz-11(C2)(D1)(C2)

Pergollizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 22 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R. 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

compound, a chromogenic compound, a chemiluminescent compound and an electron dense compound.

CLAIM 369. (PREVIOUSLY PRESENTED) The process according to claim 368, wherein said detecting step the signal generating portion comprises an enzyme.

CLAIM 370. (CANCELED)

CLAIM 371. (PREVIOUSLY PRESENTED) The process according to claim 370, wherein said detecting step the signal generating portion is selected from the group consisting of an antibody, an antigen, a hapten, a receptor, a ligand and an enzyme.

CLAIM 372. (PREVIOUSLY PRESENTED) The process according to claim 370, wherein said detecting step the signal generating portion comprises a polynucleotide sequence capable of recognizing a signal-containing moiety.

CLAIM 373. (PREVIOUSLY PRESENTED) The process according to claim 370, wherein said detecting step the signal generating portion comprises a compound capable of binding to an insoluble phase.

CLAIMS 374-375. (CANCELED)

CLAIM 376. (PREVIOUSLY PRESENTED) The process according to claim 375, wherein fixing or immobilizing the analyte takes place before forming the complex in said complex forming step.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 23 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 377. (PREVIOUSLY PRESENTED) The process according to claim 375, wherein fixing or immobilizing the analyte takes place after forming the complex in said complex forming step.

CLAIM 378. (PREVIOUSLY PRESENTED) The process according to claim 375, further comprising one or more washing steps.

CLAIM 379. (CANCELED)

CLAIM 380. (CURRENTLY AMENDED) The process according to claim ~~279~~ 379, further comprising one or more washing steps.

CLAIM 381. (CANCELLED)

CLAIM 382. (PREVIOUSLY PRESENTED) The process according to claims 449, 451 or 453, characterized in that said forming step comprises contacting said analyte with said bridging entity to form a first complex and thereafter contacting the first complex with said signalling entity to form said complex recited in said forming step.

CLAIM 383. (PREVIOUSLY PRESENTED) The process according to claims 449, 451 or 453, characterized in that said forming step comprises contacting said bridging entity with said signalling entity under conditions sufficient to form a first complex and thereafter contacting the first complex with said analyte to form said complex recited in said forming step.

CLAIM 384. (CANCELED)

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 24 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 385. (PREVIOUSLY PRESENTED) The process according to claim 384, wherein said detecting step the direct detectable signal provided by said signal generating portion comprises a radioactive compound.

CLAIM 386. (PREVIOUSLY PRESENTED) The process according to claim 384, wherein said detecting step the direct detectable signal is provided by a member selected from the group consisting of a fluorogenic compound, a phosphorescent compound, a chromogenic compound, a chemiluminescent compound and an electron dense compound.

CLAIM 387. (PREVIOUSLY PRESENTED) The process according to claim 386, wherein said detecting step the signal generating portion comprises an enzyme.

CLAIM 388. (CANCELED)

CLAIM 389. (PREVIOUSLY PRESENTED) The process according to claim 386, wherein said detecting step the signal generating portion is selected from the group consisting of an antibody, an antigen, a hapten, a receptor, a ligand and an enzyme.

CLAIM 390. (PREVIOUSLY PRESENTED) The process according to claim 388, wherein said detecting step the signal generating portion comprises a polynucleotide sequence capable of recognizing a signal-containing moiety.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 25 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 391. (PREVIOUSLY PRESENTED) The process according to claim 388, wherein said detecting step the signal generating portion comprises a compound capable of binding to an insoluble phase.

CLAIMS 392-393. (CANCELED)

CLAIM 394. (PREVIOUSLY PRESENTED) The process according to claim 393, wherein fixing or immobilizing the analyte takes place before forming the complex in said complex forming step.

CLAIM 395. (PREVIOUSLY PRESENTED) The process according to claim 393, wherein fixing or immobilizing the analyte takes place after forming the complex in said complex forming step.

CLAIM 396. (PREVIOUSLY PRESENTED) The process according to claim 393, further comprising one or more washing steps.

CLAIM 397. (CANCELED)

CLAIM 398. (PREVIOUSLY PRESENTED) The process according to claim 397, further comprising one or more washing steps.

CLAIM 399. (CANCELLED)

CLAIM 400. (PREVIOUSLY PRESENTED) The process according to claims 455, 457 or 458, characterized in that said forming step comprises contacting said fixed or immobilized analyte with said bridging entity to form a first complex and

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 26 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

thereafter contacting the first complex with said signalling entity to form said complex comprising said composition and said analyte recited in said forming step.

CLAIM 401. (PREVIOUSLY PRESENTED) The process according to claims 455, 457 or 458, characterized in that said forming step comprises contacting said bridging entity with said signalling entity under conditions sufficient to form a first complex and thereafter contacting the first complex with said fixed or immobilized analyte under conditions sufficient to form said complex comprising said composition and said analyte recited in said forming step.

CLAIM 402. (CANCELED)

CLAIM 403. (PREVIOUSLY PRESENTED) The process according to claim 400, further comprising one or more washing steps prior to detection.

CLAIM 404. (PREVIOUSLY PRESENTED) The process according to claim 401, further comprising one or more washing steps prior to detection.

CLAIM 405. (CANCELLED)

CLAIM 406. (PREVIOUSLY PRESENTED) The process according to claim 459, characterized in that said forming step comprises contacting said fixed or immobilized analyte with said bridging entity to form a first complex and thereafter contacting the first complex with said signalling entity to form said complex comprising said composition and said analyte recited in said forming step.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 27 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 407. (PREVIOUSLY PRESENTED) The process according to claim 459 characterized in that said forming step comprises contacting said bridging entity with said signalling entity under conditions sufficient to form a first complex and thereafter contacting the fixed or immobilized analyte with the first complex under conditions sufficient to form said complex comprising said composition and said analyte recited in said forming step.

CLAIM 408. (CANCELED)

CLAIM 409. (PREVIOUSLY PRESENTED) The process according to claim 406, further comprising one or more washing steps prior to detection.

CLAIM 410. (PREVIOUSLY PRESENTED) The process according to claim 407, further comprising one or more washing steps prior to detection.

CLAIM 411. (PREVIOUSLY PRESENTED) A kit for the detection in a sample of an analyte having one or more molecularly recognizable portions thereon, comprising as components thereof:

(i) a container carrying a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable portion on said analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

(ii) a container carrying more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity second portion nucleic acid sequence or segment, and one or more signal generating portions, each such portion being capable of providing a detectable signal.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 28 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 412. (PREVIOUSLY PRESENTED) A kit for the detection in a sample of an analyte having one or more molecularly recognizable portions thereon, comprising as components thereof:

a container carrying a complex which comprises:

a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable portion, and a second portion comprising one or more nucleic acid sequences or segments; and

more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity second portion, and one or more signal generating portions, each such portion being capable of providing a detectable signal.

CLAIM 413. (PREVIOUSLY PRESENTED) A kit for the detection in a sample of an analyte having one or more molecularly recognizable portions thereon, comprising as components thereof:

a container carrying more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

a container carrying more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion to form a polynucleotide hybrid, and one or more signal generating portions, capable of providing a detectable signal.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 29 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 414. (PREVIOUSLY PRESENTED) A kit for the detection in a sample of an analyte having one or more molecularly recognizable portions thereon comprising as components thereof:

more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal.

CLAIM 415. (PREVIOUSLY PRESENTED) A kit for the detection in a sample of an analyte having one or more molecularly recognizable portions thereon, comprising as components thereof:

a complex which comprises:

(i) more than one molecular bridging entity, each such, entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

(ii) more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 30 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 416. (PREVIOUSLY PRESENTED) A kit for the detection in a sample of an analyte having one or more molecularly recognizable portions thereon, comprising as components thereof:

a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more polynucleotides which have been chemically modified or artificially altered.

CLAIM 417. (PREVIOUSLY PRESENTED) A kit for the detection in a sample of an analyte having one or more molecularly recognizable portions thereon, comprising as components thereof:

a complex which comprises:

a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion to form a polynucleotide hybrid, and one or more polynucleotides which have been chemically modified or artificially altered.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 31 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 418. (PREVIOUSLY PRESENTED) The kit according to any of claim 411, 412, 413, 414 or 415, further comprising means to detect a signal from said signal generating portion.

CLAIM 419. (PREVIOUSLY PRESENTED) The kit according to claims 416 or 417, further comprising means to detect a signal from said one or more chemically modified or artificially altered polynucleotides.

CLAIM 420. (PREVIOUSLY PRESENTED) The kit according to any of claims 411, 412, 413, 414 or 415, wherein the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity is greater than 5.

CLAIM 421. (PREVIOUSLY PRESENTED) The kit according to claim 420, wherein the ratio is greater than 10.

CLAIM 422. (PREVIOUSLY PRESENTED) The kit according to any of claims 411, 412, 413, 414 or 415, wherein the ratio of the signal generating portions to the nucleic acid portion in any or all of the signalling entities is greater than 1.

CLAIM 423. (PREVIOUSLY PRESENTED) The kit according to claims 416 or 417, wherein the ratio of the one or more chemically modified or artificially altered polynucleotides to the nucleic acid portion in any or all of the signalling entities is greater than 1.

CLAIM 424. (PREVIOUSLY PRESENTED) The kit according to claim 423, wherein the ratio is greater than 5.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 32 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 425. (PREVIOUSLY PRESENTED) The kit according to claim 424, wherein the ratio is greater than 10.

CLAIM 426. (PREVIOUSLY PRESENTED) The kit according to, any of claims 411, 412, 413, 414 or 415, wherein both the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity is greater than 1, and the ratio of the signal generating portions to the nucleic acid portion in any or all of the signalling entities is greater than 1.

CLAIM 427. (PREVIOUSLY PRESENTED) The kit according to claims 416 or 417, wherein both the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity is greater than 1, and the ratio of the one or more chemically modified or artificially altered polynucleotides to the nucleic acid portion in any or all of the signalling entities is greater than 1.

CLAIM 428. (PREVIOUSLY PRESENTED) The kit according to claim 426, wherein one or both ratios are greater than 5.

CLAIM 429. (PREVIOUSLY PRESENTED) The kit according to claim 428, wherein one or both ratios are greater than 10.

CLAIM 430. (PREVIOUSLY PRESENTED) The kit according to claim 427, wherein one or both ratios are greater than 5.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 33 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 431. (PREVIOUSLY PRESENTED) The kit according to claim 430, wherein one or both ratios are greater than 10.

CLAIM 432. (PREVIOUSLY PRESENTED) The kit according to any of claims 411, 412, 413, 414, 415, 416 or 417, wherein the ratio of signalling entities to the molecular bridging entity is greater than 5.

CLAIM 433. (PREVIOUSLY PRESENTED) The kit according to claim 432, wherein the ratio is greater than 10.

CLAIM 434. (PREVIOUSLY PRESENTED) The kit according to any of claims 411, 412, 413, 414 or 415, wherein said signal generating portion is carried in a separate container from the container carrying the signalling entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion.

CLAIM 435. (PREVIOUSLY PRESENTED) The kit according to claims 416 or 417, wherein said one or more chemically modified or artificially altered polynucleotides are carried in a separate container from the container carrying the signalling entity comprising a nucleic acid, portion capable of binding to or hybridizing with said bridging entity nucleic acid second portion.

CLAIM 436. (PREVIOUSLY PRESENTED) The kit according to any of claims 411, 412, 413, 414, 415, 416 or 417, wherein said analyte comprises a biological system.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 34 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 437. (PREVIOUSLY PRESENTED) The kit according to any of claims 411, 412, 413, 414, 415, 416 or 417, further comprising one or more solid supports.

CLAIM 438. (PREVIOUSLY PRESENTED) The composition according to claims 291, 292, 293 or 294, wherein said one or more chemically modified or artificially altered polynucleotides comprise one or more nucleic acid analogs.

CLAIM 439. (PREVIOUSLY PRESENTED) The process according to claims 442, 443, 445, 447, 449, 451, 453, 455, 457, 458 or 459, wherein said step of detecting the analyte by a signal provided by said signal generating portion or portions present in said complex comprises carrying out a binding step on an insoluble phase.

CLAIM 440. (CANCELLED)

CLAIM 441. (PREVIOUSLY PRESENTED) The composition according to claim 309, wherein the nucleic acid in said molecular bridging entity recognizing first portion and said molecular bridging entity nucleic acid second portion are incapable of hybridizing to identical oligo- or polynucleotide sequences.

CLAIM 442. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:
providing the composition of claim 462;
forming a complex comprising said composition and said analyte; and
detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 35 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 443. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:

providing a composition of matter comprising:

a first part which comprises a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

a second part which comprises one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal;

forming a complex comprising said composition and said analyte; and

detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

CLAIM 444. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:

providing a composition of matter comprising a complex which comprises:

a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 36 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal;

forming a complex comprising said composition and said analyte; and

detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

CLAIM 445. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:

providing a composition of matter comprising:

a first part which comprises more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

a second part which comprises one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said more than one bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal; and

forming a complex comprising said composition and said analyte; and

detecting said analyte by a signal provided by said signal generating, portion or portions present in said complex.

CLAIM 446. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:

providing a composition of matter comprising a complex which comprises:

more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 37 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said more than one bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal;

forming a complex comprising said composition and said analyte; and

detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

CLAIM 447. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising: providing a composition of matter comprising:

a first part which comprises a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

a second part which comprises one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more chemically modified or artificially altered polynucleotides capable of providing a detectable signal;

forming a complex comprising said composition and said analyte; and

detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 38 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 448. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:

providing a composition of matter comprising a complex which comprises:

a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more chemically modified or artificially altered polynucleotides capable of providing a detectable signal;

forming a complex comprising said composition and said analyte; and

detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

CLAIM 449. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:

providing a composition of matter comprising:

a first part which comprises an analyte having one or more molecularly recognizable portions thereon;

a second part which comprises a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable analyte portion, and a second portion comprising one or more nucleic acid sequences or segments; and

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 39 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

a third part which comprises one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion or portions on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal;

forming a complex comprising the components of said composition and said analyte; and

detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

CLAIM 450. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:

providing a composition of matter comprising a complex which comprises:

an analyte having one or more molecularly recognizable portions thereon;

a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable analyte portion and a second portion comprising one or more nucleic acid sequences or segments; and

one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal;

forming a complex comprising the components of said composition and said analyte; and

detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 40 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116~~5~~ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 451. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:

providing a composition of matter comprising:

a first part which comprises an analyte having one or more molecularly recognizable portions thereon;

a second part which comprises more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable analyte portion and a second portion comprising one or more nucleic acid sequences or segments; and

a third part which comprises one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said more than one bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal;

forming a complex comprising the components of said composition and said analyte; and

detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

CLAIM 452. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:

providing a composition of matter comprising a complex which comprises:

an analyte having one or more molecularly recognizable portions thereon;

more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable analyte portion and a second portion comprising one or more nucleic acid sequences or segments; and

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 41 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

— September 20, 2005]

one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said more than one bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal;

forming a complex comprising the components of said composition and said analyte; and

detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

CLAIM 453. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:

providing a composition of matter comprising:

a first part which comprises an analyte having one or more molecularly recognizable portions thereon;

a second part which comprises a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

a third part which comprises one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more chemically modified or artificially altered polynucleotides capable of providing a detectable signal;

forming a complex comprising the components of said composition and said analyte; and

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 42 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

CLAIM 454. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:
providing a composition of matter comprising a complex which comprises:
an analyte having one or more molecularly recognizable portions thereon;
a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments;
and

one or more signalling entities substantially, incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more chemically modified or artificially altered polynucleotides capable of providing a detectable signal;
forming a complex comprising the components of said composition and said analyte; and

detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

CLAIM 455. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:
providing a composition which comprises:
a first part which comprises a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 43 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

a second part which comprises one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal;

fixing or immobilizing said analyte or a sample containing said analyte to a solid support;

forming a complex comprising, said composition and said analyte; and

detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

CLAIM 456. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:

providing a composition of matter comprising a complex which comprises: a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portion capable of providing a detectable signal;

fixing or immobilizing said analyte or a sample containing said analyte to a solid support;

forming a complex comprising said composition and said analyte; and

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 44 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

CLAIM 457. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:

providing a composition comprising:

a first part which comprises more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

a second part which comprises one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said more than one bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal;

fixing or immobilizing said analyte or a sample containing said analyte to a solid support;

forming a complex comprising said composition and said analyte; and
detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

CLAIM 458. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:

providing a composition comprising:

more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 45 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said more than one bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal;

fixing or immobilizing said analyte or a sample containing said analyte to a solid support;

forming a complex comprising said composition and said analyte; and

detecting said analyte by a signal provided by said signal generating portion or portions present in said complex.

CLAIM 459. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:

fixing or immobilizing said analyte or a sample containing said analyte to a solid support;

providing a composition comprising:

a first part which comprises a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

a second part which comprises one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 46 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

chemically modified or artificially altered polynucleotides capable of providing a detectable signal;

forming a complex comprising said composition and said analyte; and
detecting said analyte by a signal provided by means of said signal
generating portion or portions present in said complex.

CLAIM 460. (PREVIOUSLY PRESENTED) A process for detecting an analyte having one or more molecularly recognizable portions thereon, comprising:

fixing or immobilizing said analyte or a sample containing said analyte to a solid support;

providing a composition comprising a complex which comprises:
a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more chemically modified or artificially altered polynucleotides capable of providing a detectable signal;

forming a complex comprising said composition and said analyte; and
detecting said analyte by a signal provided by means of said signal
generating portion or portions present in said complex.

CLAIM 461. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said signal generating portion or said one or more chemically modified or artificially

Enz-11(C2)(D1)(C2)

Pergollizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 47 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

altered polynucleotides are capable of being detected by a binding member in an insoluble phase.

CLAIM 462. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 286, 287, 288, 289, 291, 292, 293 or 294, wherein the nucleic acid in said molecular bridging entity recognizing first portion and said molecular bridging entity nucleic acid second portion are incapable of hybridizing to identical oligo- or polynucleotide sequences.

CLAIM 463. (PREVIOUSLY PRESENTED) The composition according to any of claims 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293 or 294, wherein said molecular bridging entity comprises a polymer selected from the group consisting of a nucleic acid-protein polymer, a nucleic acid-polypeptide polymer, a nucleic acid-polysaccharide polymer and a polypeptide-polysaccharide polymer, said polymer comprising one or more chemically modified purines, one or more chemically modified pyrimidines, one or more chemically modified sugar moieties, or one or more chemically modified phosphate moieties, or a combination of any of the foregoing.

CLAIM 464. (PREVIOUSLY PRESENTED) A composition of matter comprising:
a first part which comprises a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, said analyte molecularly recognizable portion comprising a biological system selected from the group consisting of a virus or a viral component thereof and a cell or a cellular component thereof, said cell or cellular component thereof comprising a bacterium or a bacterial component thereof, said first portion being selected from the group consisting of an antigen, a

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 48 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

polyclonal or a monoclonal antibody, a hormone, a receptor, an enzyme, an allosteric effector, an enzyme substrate, an enzyme cofactor, a protein and a protein receptor, and a second portion comprising one or more nucleic acid sequences or segments; and

a second part which comprises one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portions capable of directly or indirectly providing a detectable signal, said direct signal providing signal generating portion being selected from the group consisting of a fluorogenic compound, a phosphorescent compound, a chromogenic compound, a chemiluminescent compound, an electron dense compound, an enzyme, and said indirect signal providing signal generating portion being selected from the group consisting of an antibody, an antigen, a hapten, a receptor, a ligand, an enzyme, a polynucleotide sequence capable of recognizing a signal-containing moiety, and a compound capable of binding to an insoluble phase.

CLAIM 465. (PREVIOUSLY PRESENTED) A composition of matter comprising:

a first part which comprises an analyte having one or more molecularly recognizable portions thereon, said analyte molecularly recognizable portion comprising a biological system selected from the group consisting of a virus or a viral component thereof and a cell or a cellular component thereof, said cell or cellular component thereof comprising a bacterium or a bacterial component thereof;

a second part which comprises a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 49 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

recognizable analyte portion, said first portion being selected from the group consisting of an antigen, a polyclonal or a monoclonal antibody, a hormone, a receptor, an enzyme, an allosteric effector, an enzyme substrate, an enzyme cofactor, a protein and a protein receptor, and a second portion comprising one or more nucleic acid sequences or segments; and

a third part which comprises one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion or portions on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portions capable of directly or indirectly providing a detectable signal, said direct signal providing signal generating portion being selected from the group consisting of a fluorogenic compound, a phosphorescent compound, a chromogenic compound, a chemiluminescent compound, an electron dense compound, an enzyme, and said indirect signal providing signal generating portion being selected from the group consisting of an antibody, an antigen, a hapten, a receptor, a ligand, an enzyme, a polynucleotide sequence capable of recognizing a signal-containing moiety, and a compound capable of binding to an insoluble phase.

CLAIM 466. (PREVIOUSLY PRESENTED) A composition of matter comprising:
a complex which comprises:

a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, said analyte molecularly recognizable portion comprising a biological system selected from the group consisting of a virus or a viral component thereof and a cell or a cellular component thereof, said cell or cellular component thereof comprising a bacterium or a bacterial component thereof, said first portion being

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 50 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

selected from the group consisting of an antigen, a polyclonal or a monoclonal antibody, a hormone, a receptor, an enzyme, an allosteric effector, an enzyme substrate, an enzyme cofactor, a protein and a protein receptor, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portions capable of directly or indirectly providing a detectable signal, said direct signal providing signal generating portion being selected from the group consisting of a fluorogenic compound, a phosphorescent compound, a chromogenic compound, a chemiluminescent compound, an electron dense compound, an enzyme, and said indirect signal providing signal generating portion being selected from the group consisting of an antibody, an antigen, a hapten, a receptor, a ligand, an enzyme, a polynucleotide sequence capable of recognizing a signal-containing moiety, and a compound capable of binding to an insoluble phase.

CLAIM 467. (PREVIOUSLY PRESENTED) A composition of matter comprising:
a complex which comprises:

an analyte having one or more molecularly recognizable portions thereon;
a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable analyte portion, said analyte molecularly recognizable portion comprising a biological system selected from the group consisting of a virus or a viral component thereof and a cell or a cellular component thereof, said cell or cellular component thereof comprising a bacterium or a bacterial component thereof, said first portion being selected from the group consisting of an antigen, a polyclonal or a monoclonal

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 51 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

antibody, a hormone, a receptor, an enzyme, an allosteric effector, an enzyme substrate, an enzyme cofactor, a protein and a protein receptor, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portions capable of directly or indirectly providing a detectable signal, said direct signal providing signal generating portion being selected from the group consisting of a fluorogenic compound, a phosphorescent compound, a chromogenic compound, a chemiluminescent compound, an electron dense compound, an enzyme, and said indirect signal providing signal generating portion being selected from the group consisting of an antibody, an antigen, a hapten, a receptor, a ligand, an enzyme, a polynucleotide sequence capable of recognizing a signal-containing moiety, and a compound capable of binding to an insoluble phase.

CLAIM 468. (PREVIOUSLY PRESENTED) A composition of matter comprising:

a first part which comprises more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, said analyte molecularly recognizable portion comprising a biological system selected from the group consisting of a virus or a viral component thereof and a cell or a cellular component thereof, said cell or cellular component thereof comprising a bacterium or a bacterial component thereof, said first portion being selected from the group consisting of an antigen, a polyclonal or a monoclonal antibody, a hormone, a receptor, an enzyme, an allosteric effector, an enzyme substrate, an enzyme

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 52 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

cofactor, a protein and a protein receptor, and a second portion comprising one or more nucleic acid sequences or segments; and

a second part which comprises one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said more than one bridging entity nucleic acid second portion, and one or more signal generating portions capable of directly or indirectly providing a detectable signal, said direct signal providing signal generating portion being selected from the group consisting of a fluorogenic compound, a phosphorescent compound, a chromogenic compound, a chemiluminescent compound, an electron dense compound, an enzyme, and said indirect signal providing signal generating portion being selected from the group consisting of an antibody, an antigen, a hapten, a receptor, a ligand, an enzyme, a polynucleotide sequence capable of recognizing a signal-containing moiety, and a compound capable of binding to an insoluble phase.

CLAIM 469. (PREVIOUSLY PRESENTED) A composition of matter comprising:

a first part which comprises an analyte having one or more molecularly recognizable portions thereon;

a second part which comprises more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable analyte portion, said analyte molecularly recognizable portion comprising a biological system selected from the group consisting of a virus or a viral component thereof and a cell or a cellular component thereof, said cell or cellular component thereof comprising a bacterium or a bacterial component thereof, said first portion being selected from the group consisting of an antigen, a polyclonal or a monoclonal antibody, a hormone, a

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 53 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

receptor, an enzyme, an allosteric effector, an enzyme substrate, an enzyme cofactor, a protein and a protein receptor, and a second portion comprising one or more nucleic acid sequences or segments; and

a third part which comprises one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said more than one bridging entity nucleic acid second portion, and one or more signal generating portions capable of directly or indirectly providing a detectable signal, said direct signal providing signal generating portion being selected from the group consisting of a fluorogenic compound, a phosphorescent compound, a chromogenic compound, a chemiluminescent compound, an electron dense compound, an enzyme, and said indirect signal providing signal generating portion being selected from the group consisting of an antibody, an antigen, a hapten, a receptor, a ligand, an enzyme, a polynucleotide sequence capable of recognizing a signal-containing moiety, and a compound capable of binding to an insoluble phase.

CLAIM 470. (PREVIOUSLY PRESENTED) A composition of matter comprising:
a complex which comprises:

more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, said analyte molecularly recognizable portion comprising a biological system selected from the group consisting of a virus or a viral component thereof and a cell or a cellular component thereof, said cell or cellular component thereof comprising a bacterium or a bacterial component thereof, said first portion being selected from the group consisting of an antigen, a polyclonal or a monoclonal antibody, a hormone, a receptor, an enzyme, an

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 54 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

allosteric effector, an enzyme substrate, an enzyme cofactor, a protein and a protein receptor, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said more than one bridging entity nucleic acid second portion, and one or more signal generating portions capable of directly or indirectly providing a detectable signal, said direct signal providing signal generating portion being selected from the group consisting of a fluorogenic compound, a phosphorescent compound, a chromogenic compound, a chemiluminescent compound, an electron dense compound, an enzyme, and said indirect signal providing signal generating portion being selected from the group consisting of an antibody, an antigen, a hapten, a receptor, a ligand, an enzyme, a polynucleotide sequence capable of recognizing a signal-containing moiety, and a compound capable of binding to an insoluble phase.

CLAIM 471. (PREVIOUSLY PRESENTED) A composition of matter comprising: a complex which comprises:

an analyte having one or more molecularly recognizable portions thereon; more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable analyte portion, said analyte molecularly recognizable portion comprising a biological system selected from the group consisting of a virus or a viral component thereof and a cell or a cellular component thereof, said cell or cellular component thereof comprising a bacterium or a bacterial component thereof, said first portion being selected from the group consisting of an antigen, a polyclonal or a monoclonal antibody, a hormone, a receptor, an enzyme, an

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 55 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

allosteric effector, an enzyme substrate, an enzyme cofactor, a protein and a protein receptor, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said more than one bridging entity nucleic acid second portion, and one or more signal generating portions capable of directly or indirectly providing a detectable signal, said direct signal providing signal generating portion being selected from the group consisting of a fluorogenic compound, a phosphorescent compound, a chromogenic compound, a chemiluminescent compound, an electron dense compound, an enzyme, and said indirect signal providing signal generating portion being selected from the group consisting of an antibody, an antigen, a hapten, a receptor, a ligand, an enzyme, a polynucleotide sequence capable of recognizing a signal-containing moiety, and a compound capable of binding to an insoluble phase.

CLAIM 472. (PREVIOUSLY PRESENTED) A composition of matter comprising:

a first part which comprises a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, said analyte molecularly recognizable portion comprising a biological system selected from the group consisting of a virus or a viral component thereof and a cell or a cellular component thereof, said cell or cellular component thereof comprising a bacterium or a bacterial component thereof, said first portion being selected from the group consisting of an antigen, a polyclonal or a monoclonal antibody, a hormone, a receptor, an enzyme, an allosteric effector, an enzyme substrate, an enzyme cofactor, a protein and a

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 56 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

protein receptor, and a second portion comprising one or more nucleic acid sequences or segments; and

a second part which comprises one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more chemically modified or artificially altered polynucleotides capable of directly or indirectly providing a detectable signal, said direct signal providing signal generating portion being selected from the group consisting of a fluorogenic compound, a phosphorescent compound, a chromogenic compound, a chemiluminescent compound, an electron dense compound, an enzyme, and said indirect signal providing signal generating portion being selected from the group consisting of an antibody, an antigen, a hapten, a receptor, a ligand, an enzyme, a polynucleotide sequence capable of recognizing a signal-containing moiety, and a compound capable of binding to an insoluble phase.

CLAIM 473. (PREVIOUSLY PRESENTED) A composition of matter comprising:
a complex which comprises:

a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, said analyte molecularly recognizable portion comprising a biological system selected from the group consisting of a virus or a viral component thereof and a cell or a cellular component thereof, said cell or cellular component thereof comprising a bacterium or a bacterial component thereof, said first portion being selected from the group consisting of an antigen, a polyclonal or a monoclonal antibody, a hormone, a receptor, an enzyme, an allosteric effector, an enzyme

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 57 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

substrate, an enzyme cofactor, a protein and a protein receptor, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more chemically modified or artificially altered polynucleotides capable of directly or indirectly providing a detectable signal, said direct signal providing signal generating portion being selected from the group consisting of a fluorogenic compound, a phosphorescent compound, a chromogenic compound, a chemiluminescent compound, an electron dense compound, an enzyme, and said indirect signal providing signal generating portion being selected from the group consisting of an antibody, an antigen, a hapten, a receptor, a ligand, an enzyme, a polynucleotide sequence capable of recognizing a signal-containing moiety, and a compound capable of binding to an insoluble phase.

CLAIM 474. (PREVIOUSLY PRESENTED) A composition of matter comprising:

a first part which comprises an analyte having one or more molecularly recognizable portions thereon, said analyte molecularly recognizable portion comprising a biological system selected from the group consisting of a virus or a viral component thereof and a cell or a cellular component thereof, said cell or cellular component thereof comprising a bacterium or a bacterial component thereof;

a second part which comprises a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, said first portion being selected from the group consisting of an antigen, a polyclonal or a monoclonal antibody, a hormone, a

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 58 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

receptor, an enzyme, an allosteric effector, an enzyme substrate, an enzyme cofactor, a protein and a protein receptor, and a second portion comprising one or more nucleic acid sequences or segments; and

a third part which comprises one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more chemically modified or artificially altered polynucleotides capable of directly or indirectly providing a detectable signal, said direct signal providing signal generating portion being selected from the group consisting of a fluorogenic compound, a phosphorescent compound, a chromogenic compound, a chemiluminescent compound, an electron dense compound, an enzyme, and said indirect signal providing signal generating portion being selected from the group consisting of an antibody, an antigen, a hapten, a receptor, a ligand, an enzyme, a polynucleotide sequence capable of recognizing a signal-containing moiety, and a compound capable of binding to an insoluble phase.

CLAIM 475. (PREVIOUSLY PRESENTED) A composition of matter comprising: a complex which comprises:

an analyte having one or more molecularly recognizable portions thereon; a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, said analyte molecularly recognizable portion comprising a biological system selected from the group consisting of a virus or a viral component thereof and a cell or a cellular component thereof, said cell or cellular component thereof comprising a bacterium or a bacterial component thereof, said first portion being selected from the group consisting of an antigen, a polyclonal or a monoclonal antibody, a

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 59 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

hormone, a receptor, an enzyme, an allosteric effector, an enzyme substrate, an enzyme cofactor, a protein and a protein receptor, and a second portion comprising one or more nucleic acid sequences or segments; and

one or more non-radioactive signalling entities substantially incapable of binding to or hybridizing with the molecularly recognizable portion on said analyte, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more chemically modified or artificially altered polynucleotides capable of directly or indirectly providing a detectable signal, said direct signal providing signal generating portion being selected from the group consisting of a fluorogenic compound, a phosphorescent compound, a chromogenic compound, a chemiluminescent compound, an electron dense compound, an enzyme, and said indirect signal providing signal generating portion being selected from the group consisting of an antibody, an antigen, a hapten, a receptor, a ligand, an enzyme, a polynucleotide sequence capable of recognizing a signal-containing moiety, and a compound capable of binding to an insoluble phase.

CLAIM 476. (PREVIOUSLY PRESENTED) The composition according to any of claims 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474 or 475, wherein said nucleic acid sequences or segments in the molecular bridging entity second portion, or said signalling entity nucleic acid portion, or both, are derived from the group consisting of a T even phage, a filamentous phage, and a M13 phage or an M13 phage variant.

CLAIM 477. (PREVIOUSLY PRESENTED) The composition according to any of claims 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474 or 475, wherein the ratio of the nucleic acid sequences or segments in the second portion to the

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 60 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

first portion of the molecular bridging entity is selected from the group consisting of a number greater than 5 and a number greater than 10, and wherein the ratio of the signal generating portions or the one or more chemically modified or artificially altered polynucleotides to the nucleic acid portion in any or all of the signalling entities is selected from the group consisting of a number greater than 5 and a number greater than 10.

CLAIM 478. (PREVIOUSLY PRESENTED) The composition according to claim 477, wherein both the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity, and the ratio of the signal generating portions or the one or more chemically modified or artificially altered polynucleotides to the nucleic acid portion in any or all of the signalling entities is selected from the group consisting of a number greater than 1, a number greater than 5 and a number greater than 10.

CLAIM 479. (PREVIOUSLY PRESENTED) A kit for the detection in a sample of an analyte having one or more molecularly recognizable portions thereon, comprising as components thereof:

(i) a container carrying a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable portion on said analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

a container carrying more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity second portion nucleic acid sequence or segment, and one or more signal generating portions, each such portion being capable of providing a detectable signal;

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 61 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)
-- September 20, 2005]

wherein the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity is selected from a number greater than 5 and a number greater than 10; or

wherein both the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity and the ratio of the signal generating portions to the nucleic acid portion in any or all of the signalling entities is selected from a number greater than 1, a number greater than 5 and a number greater than 10.

CLAIM 480. (PREVIOUSLY PRESENTED) A kit for the detection in a sample of an analyte having one or more molecularly recognizable portions thereon, comprising as components thereof:

a container carrying a complex which comprises:

a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable portion, and a second portion comprising one or more nucleic acid sequences or segments; and more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity second portion, and one or more signal generating portions, each such portion being capable of providing a detectable signal;

wherein the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity is selected from a number greater than 5 and a number greater than 10; or

wherein both the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity and the ratio of the signal generating portions to the nucleic acid portion in any or all of the

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 62 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

signalling entities is selected from a number greater than 1, a number greater than 5 and a number greater than 10.

CLAIM 481. (PREVIOUSLY PRESENTED) A kit for the detection in a sample of an analyte having one or more molecularly recognizable portions thereon, comprising as components thereof:

a container carrying more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

a container carrying more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion to form a polynucleotide hybrid, and one or more signal generating portions capable of providing a detectable signal; wherein the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity is selected from a number greater than 5 and a number greater than 10; or

wherein both the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity and the ratio of the signal generating portions to the nucleic acid portion in any or all of the signalling entities is selected from a number greater than 1, a number greater than 5 and a number greater than 10.

CLAIM 482. (PREVIOUSLY PRESENTED) A kit for the detection in a sample of an analyte having one or more molecularly recognizable portions thereon, comprising as components thereof:

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 63 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal;

wherein the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity is selected from a number greater than 5 and a number greater than 10; or

wherein both the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity and the ratio of the signal generating portions to the nucleic acid portion in any or all of the signalling entities is selected from a number greater than 1, a number greater than 5 and a number greater than 10.

CLAIM 483. (PREVIOUSLY PRESENTED) A kit for the detection in a sample of an analyte having one or more molecularly recognizable portions thereon, comprising as components thereof:

a complex which comprises:

(i) more than one molecular bridging entity, each such entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

(ii) more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 64 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

nucleic acid second portion, and one or more signal generating portions capable of providing a detectable signal;

wherein the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity is selected from a number greater than 5 and a number greater than 10; or

wherein both the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity and the ratio of the signal generating portions to the nucleic acid portion in any or all of the signalling entities is selected from a number greater than 1, a number greater than 5 and a number greater than 10.

CLAIM 484. (PREVIOUSLY PRESENTED) A kit for the detection in a sample of an analyte having one or more molecularly recognizable portions thereon, comprising as components thereof:

a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion, and one or more polynucleotides which have been chemically modified or artificially altered;

wherein the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity is selected from a number greater than 5 and a number greater than 10; or

wherein one or both the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity and the ratio

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 65 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

of the one or more chemically modified or artificially altered polynucleotides to the nucleic acid portion in any or all of the signalling entities is selected from a number greater than 1, a number greater than 5 and a number greater than 10.

CLAIM 485. (PREVIOUSLY PRESENTED) A kit for the detection in a sample of an analyte having one or more molecularly recognizable portions thereon, comprising as components thereof:

a complex which comprises:

a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with a molecularly recognizable portion on an analyte, and a second portion comprising one or more nucleic acid sequences or segments; and

more than one non-radioactive signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion to form a polynucleotide hybrid, and one or more polynucleotides which have been chemically modified or artificially altered;

wherein the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity is selected from a number greater than 5 and a number greater than 10; or

wherein one or both the ratio of the nucleic acid sequences or segments in the second portion to the first portion of the molecular bridging entity and the ratio of the one or more chemically modified or artificially altered polynucleotides to the nucleic acid portion in any or all of the signalling entities is selected from a number greater than 1, a number greater than 5 and a number greater than 10.

CLAIM 486. (PREVIOUSLY PRESENTED) The kit of any of claims 479, 480, 481, 482 or 483, wherein said signal generating portion is carried in a separate container

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 66 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

from the container carrying the signalling entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion.

CLAIM 487. (PREVIOUSLY PRESENTED) The kit of claims 484 or 485, wherein said one or more chemically modified or artificially altered polynucleotides are carried in a separate container from the container carrying the signalling entity comprising a nucleic acid portion capable of hybridizing with said bridging entity nucleic acid second portion.

CLAIM 488. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 443, said kit comprising as components thereof the first part and the second part of the composition provided in said process.

CLAIM 489. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 444, said kit comprising as components thereof said complex provided as a composition in said process.

CLAIM 490. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 445, said kit comprising as components thereof said first part and said second part provided as a composition in said process.

CLAIM 491. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 446, said kit comprising as components thereof said complex provided as a composition in said process.

Enz-11(C2)(D1)(C2)

Pergollzzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 67 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

— September 20, 2005]

CLAIM 492. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 447, said kit comprising as components thereof said first part and said second part provided as a composition in said process.

CLAIM 493. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 448, said kit comprising as components thereof said complex provided as a composition in said process.

CLAIM 494. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 449, said kit comprising as components thereof said first part, said second part and said third part provided as a composition in said process.

CLAIM 495. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 450, said kit comprising as components thereof said complex provided as a composition in said process.

CLAIM 496. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 451, said kit comprising as components thereof said first part, said second part and said third part provided as a composition in said process.

CLAIM 497. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 452, said kit comprising as components thereof said complex provided as a composition in said process.

CLAIM 498. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 453, said kit comprising as components thereof said first part, said second part and said third part provided as a composition in said process.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 68 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

— September 20, 2005]

CLAIM 499. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 454, said kit comprising as components thereof said complex provided as a composition in said process.

CLAIM 500. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 455, said kit comprising as components thereof said first part and said second part provided as a composition and said solid support in said process.

CLAIM 501. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 456, said kit comprising as components thereof said complex provided as a composition and said solid support in said process.

CLAIM 502. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 457, said kit comprising as components thereof said first part and said second part provided as a composition and said solid support in said process.

CLAIM 503. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 458, said kit comprising as components thereof said composition provided and said solid support in said process.

CLAIM 504. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 459, said kit comprising as components thereof said first part and said second part provided as a composition and said solid support in said process.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 69 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

– September 20, 2005]

CLAIM 505. (PREVIOUSLY PRESENTED) A kit for use in carrying out the process of claim 460, said kit comprising as components thereof said complex provided as a composition and said solid support in said process.

CLAIM 506. (CANCELLED)

CLAIM 507. (PREVIOUSLY PRESENTED) A polynucleotide sequence covalently attached to a monoclonal antibody.

CLAIM 508. (PREVIOUSLY PRESENTED) A polynucleotide sequence covalently attached to a lectin.

509. (CANCELLED)

CLAIM 510. (PREVIOUSLY PRESENTED) A polynucleotide sequence covalently attached to a hormone receptor.

CLAIM 511. (PREVIOUSLY PRESENTED) A polynucleotide sequence covalently attached to a hormone.

CLAIMS 512-515. (CANCELLED)

CLAIMS 516-527. (CANCELLED)

CLAIM 528. (PREVIOUSLY PRESENTED) A circular DNA molecule covalently attached to a non-radiolabeled signal generating moiety that comprises an enzyme.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 70 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.1165 (Following The September 8, 2005 Advisory Action)

— September 20, 2005]

CLAIM 529. (PREVIOUSLY PRESENTED) A circular DNA molecule comprising a polynucleotide that encodes part or all of a gene, wherein the DNA molecule is covalently attached to a non-radiolabeled signal generating moiety that comprises biotin.

CLAIM 530. (PREVIOUSLY PRESENTED) A circular DNA molecule comprising a polynucleotide that encodes part or all of a gene, wherein the DNA molecule is covalently attached to a non-radiolabeled signal generating moiety that comprises an antibody.

CLAIM 531. (PREVIOUSLY PRESENTED) A circular DNA molecule comprising a polynucleotide that encodes part or all of a gene, wherein the DNA molecule is covalently attached to a non-radiolabeled signal generating moiety that comprises a fluorogenic compound.

CLAIM 532. (PREVIOUSLY PRESENTED) The process of claim 443, wherein said analyte is a DNA sequence, said bridging entity is a single-stranded DNA sequence, and said signalling entities are single-stranded DNA sequences.

CLAIM 533. (PREVIOUSLY PRESENTED) The process of claim 532, wherein said bridging entity is derived from a filamentous phage.

CLAIM 534. (PREVIOUSLY PRESENTED) The process of claim 533, wherein said signalling entities are derived from filamentous phages.

CLAIM 535. (PREVIOUSLY PRESENTED) The process of claim 534, wherein said bridging entity codes for a gene product or fragment thereof, and said forming step

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 71 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.116\$ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

comprises either (i) contacting said analyte with said bridging entity to form a first complex and thereafter contacting said first complex with said signalling entities to form said detectable complex or (ii) contacting said bridging entity with said signalling entities to form a first complex and thereafter contacting said first complex with said analyte to form said detectable complex.

CLAIM 536. (PREVIOUSLY PRESENTED) The process of claim 443, wherein said analyte is a polynucleotide, said one or more nucleic acid sequences or segments of said second portion are repeating low complexity nucleic acid sequences or segments, and said one or more nucleic acid sequences or segments of said second portion are incapable of hybridizing to the analyte.

CLAIM 537. (PREVIOUSLY PRESENTED) The process of claim 536, wherein said signal is amplified because the ratio of the signalling entities to the bridging entity exceeds 5.

CLAIM 538. (PREVIOUSLY PRESENTED) The kit of claim 411, wherein said analyte is a polynucleotide, said one or more nucleic acid sequences or segments of said second portion are repeating low complexity nucleic acid sequences or segments, and said one or more nucleic acid sequences or segments of said second portion are incapable of hybridizing to the analyte.

CLAIM 539. (PREVIOUSLY PRESENTED) The kit of claim 538, wherein said signal is amplified because the ratio of the signalling entities to the bridging entity exceeds 5.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 72 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

— September 20, 2005]

CLAIM 540. (PREVIOUSLY PRESENTED) The process of claim 443, wherein said analyte is a single-stranded DNA sequence fixed to a solid support, said bridging entity comprises non-naturally occurring or artificially modified DNA, said bridging entity first portion comprises a linear single-stranded polynucleotide sequence, said bridging entity first portion is covalently bound to said bridging entity second portion, and said bridging entity second portion is single-stranded and linear and comprises more than one of said nucleic acid sequences or segments.

CLAIM 541. (PREVIOUSLY PRESENTED) The process of claim 540, wherein said signalling entities are single-stranded oligo- or polynucleotide sequences, said bridging entity first portion is capable of encoding a gene product or fragment thereof, and the process further comprises one or more washing steps prior to detection.

CLAIM 542. (PREVIOUSLY PRESENTED) The composition of claim 283, wherein said analyte is a single-stranded DNA sequence fixed to a solid support, said bridging entity comprises non-naturally occurring or artificially modified DNA, said bridging entity first portion comprises a linear single-stranded polynucleotide sequence, said bridging entity first portion is covalently bound to said bridging entity second portion, and said bridging entity second portion is single-stranded and linear and comprises more than one of said nucleic acid sequences or segments.

CLAIM 543. (PREVIOUSLY PRESENTED) The composition of claim 542, wherein said signalling entities are single-stranded oligo- or polynucleotide sequences and said bridging entity first portion is capable of encoding a gene product or fragment thereof.

Enz-11(C2)(D1)(C2)

Pergolizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 73 [Supplemental Amendment To Applicants' July 7, 2005 Amendment
Under 37 C.F.R 1.116⁵ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

CLAIM 544. (PREVIOUSLY PRESENTED) The kit of claim 411, wherein said analyte is a single-stranded DNA sequence fixed to a solid support, said bridging entity comprises non-naturally occurring or artificially modified DNA, said bridging entity first portion comprises a linear single-stranded polynucleotide sequence, said bridging entity first portion is covalently bound to said bridging entity second portion, and said bridging entity second portion is single-stranded and linear and comprises more than one of said nucleic acid sequences or segments.

CLAIM 545. (PREVIOUSLY PRESENTED) The kit of claim 544, wherein said signalling entities are single-stranded oligo- or polynucleotide sequences and said bridging entity first portion is capable of encoding a gene product or fragment thereof.

CLAIM 546. (PREVIOUSLY PRESENTED) A kit for the detection in a sample of an analyte having one or more molecularly recognizable portions thereon, comprising as components thereof:

(i) a container carrying a molecular bridging entity comprising a first portion capable of recognizing and binding to or hybridizing with said molecularly recognizable portion on said analyte, and a second portion comprising one, or more nucleic acid sequences or segments; and

(ii) a container carrying more than one signalling entity, each such entity comprising a nucleic acid portion capable of hybridizing with said bridging entity second portion nucleic acid sequence or segment, and one or more signal generating portions, each such portion being capable of providing a detectable signal,

wherein said analyte is a polynucleotide, said one or more nucleic acid sequences or segments of said second portion are repeating low complexity nucleic

Enz-11(C2)(D1)(C2)

Pergollizzi et al.; Serial No.: 08/479,995 (Filed June 7, 1995)

Page 74 [Supplemental Amendment To Applicants' July 7, 2005 Amendment

Under 37 C.F.R 1.116§ (Following The September 8, 2005 Advisory Action)

-- September 20, 2005]

acid sequences or segments, and said one or more nucleic acid sequences or segments of said second portion are incapable of hybridizing to the analyte.

CLAIM 547. (PREVIOUSLY PRESENTED) The kit of claim 546, wherein said signal is amplified because the ratio of the signalling entities to the bridging entity exceeds 5.

CLAIMS 548-549. (CANCELLED).

CLAIM 550. (NEW) A polynucleotide sequence covalently attached to an antibody.

CLAIM 551. (NEW) The polynucleotide sequence of claim 550, wherein said antibody comprises a polyclonal antibody.

CLAIM 552. (NEW) The polynucleotide sequence of claim 550, wherein said polynucleotide sequence comprises a signal generating portion.

* * * * *

Enz-11(C2)(D1)(C2)